copanlisib,eribulin mesylate
bayer,eisai pharmaceutical
['eribulin', 'tnbc', 'copanlisib', 'breast']
nusayba bagegni, md, presents a phase i/ii trial evaluating the safety and efficacy of eribulin in combination with copanlisib in patients with metastatic triple-negative breast cancer (tnbc) poster (#103) at 8:00am at mccormick place, hall a. #asco22 
A National Cancer Institute Comprehensive Cancer Center and member of the National Comprehensive Cancer Network